The ultimate goals of treating SHPT are to normalize mineral metabolism,prevent bone disease, and prevent extraskeletal manifestations of the altered biochemical processes. The in D, and iPTH are used as surrogate measures of disease progression. It is important to identify SHPT early. Abnormalities can occur subtly, usually without any symptoms, and may progress to cause more complications if not detected early. Until recently, it was thought that hyperphosphatemia was the earliest sign of SHPT and bone metabolism disorders. However, when patients reach Stage 3 CKD,it is highly probable that none of the biochemical parameters routinely assessed will be abnormal. In fact, the iPTH level is often increased before clinical hyperphosphatemia occurs. 17–19 For this reason, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KQODI) guidelines recommend that all patients with a GFR< 60 ml/min/1.73 m dos undergo evaluation of serum calcium,phosphorus, and iPTH levels (Table 1). Additionally, if the iPTH concentration exceeds the CKD stage-specific target, the 25(OH)D level (precursor of activated vitamin D2,step 3) should be assessed and treated. Hopefully, earlier identification and assessment of SHPT will improve bone and mineral metabolism in CKD and reduce its associated complications (e.g., fractures, pain, and cardiovascular calcification).
For patients with Stage 3 or Stage 4 CKD, one of the first abnormalities noted on evaluation may be an isolated increase in iPTH. If the iPTH concentration exceeds the target range, the serum 25(OH)D concentration should be measured, and if that is found to be < 30 ng/ml, ergocalciferol (vitamin D2) therapy should be initiated(Table 2). If the concentration of 25(OH)D is > 30 ng/ml and the iPTH concentration exceeds the target range, an activated vitamin D agent should be initiated(Table 3). 20 Regardless of which vitamin D agent is used, the calcium and phosphorus concentrations must be monitored and maintained within the target range to prevent the precipitation of calcium in soft tissue and vasculature. (suite…)Read more
JEROME MASSA 2017. All RIGHTS RESERVED.
DESIGNED AND DEVELOPED BY GET82DESIGN.FR